167 related articles for article (PubMed ID: 29087126)
1. [Myelosupression induced by linezolid: a pediatric case].
Ballesteros García MDM; Orós Milián ME; Díaz Velázquez E; Alarcón Alacio MT; Galán Del Río P
Arch Argent Pediatr; 2017 Dec; 115(6):e420-e423. PubMed ID: 29087126
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for Gram-positive bacterial infections.
Kato H; Hagihara M; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2021 Aug; 27(8):1143-1150. PubMed ID: 33727025
[TBL] [Abstract][Full Text] [Related]
3. Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
Zhou D; Shi T; Zhao S; Zhu J; Zhu L; Yang X; Xie W; Ye X
J Clin Pharm Ther; 2020 Aug; 45(4):755-758. PubMed ID: 32403181
[TBL] [Abstract][Full Text] [Related]
4. Linezolid-Induced anemia and thrombocytopenia.
Waldrep TW; Skiest DJ
Pharmacotherapy; 2002 Jan; 22(1):109-12. PubMed ID: 11794421
[TBL] [Abstract][Full Text] [Related]
5. Linezolid-induced rare triad of hypoglycaemia, bone marrow suppression and hyponatraemia in elderly.
Singhania SVK; Shenoy S; Kapoor D
J Clin Pharm Ther; 2020 Apr; 45(2):376-378. PubMed ID: 31657870
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia with Tedizolid and Linezolid.
Lee EY; Caffrey AR
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of linezolid in bone marrow transplantation patients.
Hogan HL; Hachem RY; Neuhauser M; Raad II; Coyle E
J Pharm Pract; 2010 Aug; 23(4):352-7. PubMed ID: 21507835
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study.
Senneville E; Legout L; Valette M; Yazdanpanah Y; Giraud F; Beltrand E; Obert G; Dubreuil L; Migaud H; Mouton Y
J Antimicrob Chemother; 2004 Oct; 54(4):798-802. PubMed ID: 15329363
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
[TBL] [Abstract][Full Text] [Related]
10. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
11. [Linezolid-induced lactic acidosis - a brief overview with a case report].
Pazderkovák J; Kotora V; Dlouhý P; Bartoš H
Klin Mikrobiol Infekc Lek; 2019 Sep; 25(3):92-96. PubMed ID: 31904104
[TBL] [Abstract][Full Text] [Related]
12. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment.
Plachouras D; Giannitsioti E; Athanassia S; Kontopidou F; Papadopoulos A; Kanellakopoulou K; Giamarellou H
Clin Infect Dis; 2006 Nov; 43(9):e89-91. PubMed ID: 17029128
[TBL] [Abstract][Full Text] [Related]
13. Hematologic effects of linezolid in young children.
Meissner HC; Townsend T; Wenman W; Kaplan SL; Morfin MR; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S186-92. PubMed ID: 14520145
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis.
Berenguer N; Ferrández O; Barbosa F; Urbina O; Espona M; Grau S
J Chemother; 2012 Aug; 24(4):226-8. PubMed ID: 23040688
[TBL] [Abstract][Full Text] [Related]
15. Linezolid for the treatment of adults with bone and joint infections.
Falagas ME; Siempos II; Papagelopoulos PJ; Vardakas KZ
Int J Antimicrob Agents; 2007 Mar; 29(3):233-9. PubMed ID: 17204407
[TBL] [Abstract][Full Text] [Related]
16. Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.
Jones SJ; Nichols KR; DeYoung HL; Cox EG; Knoderer CA
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):272-5. PubMed ID: 26407433
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination.
Kaya Kılıç E; Bulut C; Sönmezer MÇ; Ozel Ö; Ataman Hatipoğlu Ç; Tuncer Ertem G; Tülek N; Kınıklı S
J Infect Dev Ctries; 2019 Oct; 13(10):886-891. PubMed ID: 32084018
[TBL] [Abstract][Full Text] [Related]
18. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.
Ichie T; Suzuki D; Yasui K; Takahashi H; Matsuda M; Hayashi H; Sugiura Y; Sugiyama T
J Clin Pharm Ther; 2015 Jun; 40(3):279-84. PubMed ID: 25732525
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and risk factors for severe linezolid-associated thrombocytopenia in pediatric patients: An analysis of a public database.
Yang S; Guo W; Chen M; Hu J; Feng N; Ju M; Qian Y
Medicine (Baltimore); 2023 Jun; 102(24):e34059. PubMed ID: 37327288
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neuropathy in an adolescent treated with linezolid.
Linam WM; Wesselkamper K; Gerber MA
Pediatr Infect Dis J; 2009 Feb; 28(2):149-51. PubMed ID: 19116599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
